Our findings suggest a critical role of Gata3 loss in driving CSC function and metastasis, and support the development of therapeutic drugs enhancing GATA3 function or targeting its downstream pathway to treat metastatic breast cancers. This evidence concerns the gene GATA3 and breast cancer.